# DR Reddys Laboratories Ltd: financial statements, quarterly

RDY · NYSE · CIK 1135951 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/rdy.md) · [Financials](/companies/rdy/financials.md) · [Filings](/companies/rdy/filings.md) · [Insiders](/companies/rdy/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rdy/financials.md?period=annual).

## Balance sheet

| Line item | Unit | FY2018 (2018-03-31) | FY2019 (2019-03-31) | FY2020 (2020-03-31) | FY2021 (2021-03-31) | FY2022 (2022-03-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [41.0](/filings/0001575872-18-000142.md) | [32.0](/filings/0001575872-19-000144.md) | [27.0](/filings/0001575872-20-000145.md) | [203](/filings/0001575872-21-000138.md) | [196](/filings/0001575872-22-000576.md) | [70.0](/filings/0001575872-23-000951.md) | [85.0](/filings/0001575872-24-000660.md) | [172](/filings/0001575872-25-000393.md) |
| Current assets | $m | [1,684](/filings/0001575872-18-000142.md) | [1,656](/filings/0001575872-19-000144.md) | [1,729](/filings/0001575872-20-000145.md) | [2,027](/filings/0001575872-21-000138.md) | [2,397](/filings/0001575872-22-000576.md) | [2,518](/filings/0001575872-23-000951.md) | [2,976](/filings/0001575872-24-000660.md) | [2,928](/filings/0001575872-25-000393.md) |
| Total assets | $m | [3,465](/filings/0001575872-18-000142.md) | [3,259](/filings/0001575872-19-000144.md) | [3,081](/filings/0001575872-20-000145.md) | [3,630](/filings/0001575872-21-000138.md) | [3,860](/filings/0001575872-22-000576.md) | [3,916](/filings/0001575872-23-000951.md) | [4,650](/filings/0001575872-24-000660.md) | [5,772](/filings/0001575872-25-000393.md) |
| Current liabilities | $m | [1,070](/filings/0001575872-18-000142.md) | [863](/filings/0001575872-19-000144.md) | [966](/filings/0001575872-20-000145.md) | [1,140](/filings/0001575872-21-000138.md) | [1,239](/filings/0001575872-22-000576.md) | [1,044](/filings/0001575872-23-000951.md) | [1,152](/filings/0001575872-24-000660.md) | [1,527](/filings/0001575872-25-000393.md) |
| Total liabilities | $m | [1,523](/filings/0001575872-18-000142.md) | [1,232](/filings/0001575872-19-000144.md) | [1,025](/filings/0001575872-20-000145.md) | [1,264](/filings/0001575872-21-000138.md) | [1,348](/filings/0001575872-22-000576.md) | [1,106](/filings/0001575872-23-000951.md) | [1,284](/filings/0001575872-24-000660.md) | [1,825](/filings/0001575872-25-000393.md) |
| Shareholders' equity | $m | [1,942](/filings/0001575872-18-000142.md) | [2,027](/filings/0001575872-19-000144.md) | [2,056](/filings/0001575872-20-000145.md) | [2,366](/filings/0001575872-21-000138.md) | [2,511](/filings/0001575872-22-000576.md) | [2,810](/filings/0001575872-23-000951.md) | [3,366](/filings/0001575872-24-000660.md) | [3,903](/filings/0001575872-25-000393.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Total liabilities: ifrs-full:Liabilities
- Shareholders' equity: ifrs-full:Equity, ifrs-full:EquityAttributableToOwnersOfParent

Shares outstanding: 834,656,970 at 2026-03-31, from the cover of the [20-F filed 2026-05-29](/filings/0001575872-26-000381.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.